Science Stories
Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments.
Post-traumatic stress disorder (PTSD) is a common psychiatric condition affecting approximately 10 million Americans that can result from actual or threatened traumatic events and experiences. Learn more about the prevalence of this complex psychiatric condition and Jazz’s efforts to address the significant unmet need for patients.
Dravet syndrome is a rare, severe, lifelong form of treatment-resistant epilepsy that typically begins in the first year of life.
The onset of cardiovascular events and risk factors is high among those living with narcolepsy, even among patients who do not have a history of these cardiovascular conditions. Learn more about the key findings of the CV-BOND study, recently presented by Rami H. Ben-Joseph, Ph.D., head of big data real world evidence at Jazz.